1,0
27 mei 2022
Voormalige werknemer, meer dan 5 jaar
Vancouver, BC
Aanbevelen
Goedkeuring directeur
Zakelijk vooruitzicht
Pluspunten
Zanidatamab is an excellent asset
Minpunten
- Talented & experienced group of scientists that developed Zanidatamab are no longer at Zymeworks - Senior Scientific leadership does not have the necessary drug development experience - Success of pipeline projects doesn't matter, company is treading water to get to a sale - CEO has no history developing medicine or building companies. His history is dominated by breaking apart and selling assets. - Former CFO, at least partly responsible for the cratering of the company, is allowed to remain and transition to COO. - Company still talks about its values as though they determine corporate behavior